• Designing the Indigenous Allogeneic Cancer Vaccine for Immunotherapy of Metastatic Colorectal Cancer Patients
  • Samane Mohammadzadeh,1,* Mohammad Hassan Emami,2 Fatemeh Maghool,3 Safoora Mohammadzadeh,4
    1. Poursina Hakim Digestive Diseases Research Center, Isfahan University of medical sciences, Isfahan, Iran
    2. Poursina Hakim Digestive Diseases Research Center, Isfahan University of medical sciences, Isfahan, Iran
    3. Poursina Hakim Digestive Diseases Research Center, Isfahan University of medical sciences, Isfahan, Iran
    4. Poursina Hakim Digestive Diseases Research Center, Isfahan University of medical sciences, Isfahan, Iran


  • Introduction: Colorectal Cancer (CRC) is the fourth most common cancer in Iran. In some patient’s surgery and chemotherapy as the standard methods could not prevent cancer recurrence. Therefore, in recent years, cancer vaccines or cancer cell immunotherapy have been used to encourage suitable responses against tumor antigens. One of the cancer vaccines for prevention of colon cancer recurrence after surgery is an allogeneic colon cancer vaccine, which is contained allogeneic cancer cells and adjuvant BCG (Calmette-Guerin bacillus). Usage of this vaccine could increase survival of patients with metastatic colon cancer. The aim of this study is designing the different allogeneic cancer vaccine for metastatic colorectal cancer patients in Iran.
  • Methods: This study designed the indigenous allogeneic cancer vaccine, which is contained some metastatic and non-metastatic colon and rectal cell lines. These cells express mutation form of KRAS, BRA, PI3KA, and P53, and also express high levels of APC, CEA, CD133 and EP cam. Part of these cells have miss match instability. This cancer vaccine will be able to use for metastatic colorectal cancer patients with resectable or non-resectable tumors in two periods of times, 3 doses before the chemotherapy and also 3 doses after the chemotherapy.
  • Results: The new indigenous allogeneic cancer vaccine for immunotherapy of metastatic colorectal cancer patients by non-tumorigenic colorectal cell lines was approved in Isfahan University of medical sciences and also Iranian Registry of Clinical Trials.
  • Conclusion: Our study is the first immunotherapy by indigenous allogeneic colorectal cancer vaccine in Iran. This immunotherapy provides the active specific immunotherapies for metastatic CRC patients with the lower cost in Iran.
  • Keywords: Allogeneic Cancer Vaccine, Immunotherapy, Metastasis, Colorectal Cancer